Join us as our Chief Business Officer, Rachel Thu Nguyen, represents Eversyn and connects with the DxPx community to explore drug discovery innovation, platform technologies, and collaborative research opportunities.
We look forward to meaningful conversations and new partnerships, see you there! 🌍💡

📍 Location: Munich, Germany
🗓️ Dates: February 5–6, 2026

During the BioFIT Start-up Slams, BioTeam Paris-Saclay recognized outstanding start-ups for their innovation and growth potential in the health and biotech ecosystem.
We’re proud to share that eversyn GmbH was selected as a 2025 award winner, receiving both the IncubAlliance Award and the Genopole Award.

We were delighted to be part of the Korea x Germany startup exchange led by AHK Korea.
Start2 Connect Korea x Germany highlighted the power of cross-border collaboration, connecting founders, innovators, and investors across both ecosystems. The conversations underscored Germany’s role as a gateway to Europe and new opportunities for global growth.
At eversyn, we believe life-science innovation, especially in emerging fields like the sugar code, advances fastest through strong international partnerships.

We are excited to announce a collaboration with Dr. Vassilis Triantis to advance eversyn’s bioactive complex oligosaccharides towards commercialization. Bringing together Dr. Triantis’s expertise in immunology, gastrointestinal physiology, and molecular biology with eversyn’s proprietary cell-free oligosaccharide platform, this partnership strengthens our scientific foundation.
Together, we aim to generate robust experimental evidence, validate health benefits, and translate cutting-edge oligosaccharide science into real-world impact.

We’re excited to share that eversyn GmbH has been selected for the Start-up Slams at #BioFIT2025 🚀
On December 2–3 in Strasbourg, we’ll be pitching our early-stage technology alongside an inspiring cohort of innovators shaping the future of life sciences. We’re proud to represent our vision of unlocking the #sugarcode and advancing glycan-driven innovation, and we look forward to engaging with partners, collaborators, and the wider BioFIT community.

At eversyn, we’re proud to help shape the future of life sciences by exploring the vast potential of the #sugarcode. Inspired by visionary minds like Dr. Nam-Hai Hoang and moments such as #FallingWalls, we’re driven by a bold question: what if the next revolution lies in sugars? If “life is information,” then the next frontier is unlocking nature’s third and perhaps most complex script: the #sugarcode. #Glycans carry immense biological information, and we’re only beginning to scratch the surface. So which are the next walls to fall? It’s good to dream again and even better to dream big with eversyn GmbH

eversyn is proud to participate in the recent Life Science Sachsen-Anhalt e.V. general meeting, where members shared their visions for the future of the industry. The event, highlighted by pitches from startups and partners, demonstrated the diverse and effective innovation thriving in the region. We thank State Secretary Stefanie Pötzsch for her kind words about the Life Science Cluster, confirming that collaboration is actively shaping the future of Saxony-Anhalt's life science industry.

Our Co-Founder and Managing Director, Dr. Thomas Rexer, is set to pitch at the prestigious 'Pitch Perfect: Boost the EU Bioeconomy 2025' event! He will be presenting on November 24–25 at the Sheraton Brussels Airport. Dr. Rexer looks forward to meeting fellow innovators, exchanging ideas, and exploring new opportunities to drive Europe’s bio-based future forward.

eversyn is marking an exciting milestone: we are launching our first nucleotide azido sugar, CMP-C9-Azido-Sialic Acid! This breakthrough is broadening our impact in key therapeutic areas, including Antibody-drug conjugates (ADC), Peptide-drug conjugates (PDC), and Glycoconjugate vaccine development. Each innovation is taking us closer to translating complex science into tangible hope for patients.

Our CEO, Dr. Thomas Rexer will be speaking on stage:
📍 Tokyo Innovation Base
⌚ eversyn's pitch time: Oct 21, 13:30 - 14:05
🎙 Pitch category: Sustainability & Smart Infrastructure

We’re excited to announce eversyn will be exhibiting at CPHI Frankfurt 2025 from October 28–30 at Messe Frankfurt! Visit us at stand 4S168 to discuss practical pathways for scaling up production from pilot to industrial scale in biotech, pharma, and sustainable manufacturing. Our team, including Dr. Thomas Rexer, Dr. Nam-Hai Hoang, and Dr. Daniel Last, looks forward to connecting, exchanging ideas, and exploring new collaboration opportunities in the global pharmaceutical community.

eversyn successfully utilized its three minutes in the spotlight, pitching before a panel of potential investors at the Investforum Pitch-Day 2025. This event provided an unforgettable platform for our team to present our innovative business model. Following the stage pitch, we are now transitioning to the Read Deck phase, a key opportunity to continue targeted discussions and secure further investment to accelerate our mission.

Eversyn develops enzyme-based processes for the production of highly complex sugars – cell-free. Applications range from baby food to biopharmaceuticals.

Our team, Dr. Daniel Last and Rachel Thu Nguyen, will be on site. Don't forget to drop by our booth No. PE13 (The Platz hall - 2F) at COEX Seoul between 26 - 28 Aug.

Last week, we wrapped an incredible day with the Max-Planck-Förderstiftung Start-up Accelerator, featuring a packed agenda of insight, innovation, and connection.

We’re excited to announce our participation in the 22nd European Carbohydrate Symposium (eurocarb 22), taking place July 6–10, 2025, at the Baltic Philharmonic in Gdańsk, Poland.

Following Daniel’s adventure in Canada, Sebastian Bruno Kleeberg and Rachel Thu Nguyen are representing us at Chemspecs 2025 in Köln. This year’s exhibition has been especially memorable, as it coincided with a WWII bomb defusal in the city.

Glyco27 brought together over 400 researchers, industry experts, and emerging talent in glycomics from around the world for a week of cutting-edge science, meaningful connections, and celebration in Edmonton.

German Accelerator empowers German startups to scale globally. They take high potential companies on a fast-paced learning journey to understand, discover, and access the world’s leading innovation hubs in the U.S., Asia, and South America.

This recognition celebrates innovation at the crossroads of food, technology, and sustainability. Being selected from food innovators across 70+ countries is a true honor.

The funding round was led by bmp ventures with IBG funds, and saw co-investments from the Max Planck Society, Max Planck Foundation’s MPF Start-Up Accelerator GmbH, and a strategic business angel.

Enjoy free trials of our:
• High-purity activated sugars
• Next-gen glycoengineering enzymes

eversyn took part in Start2 Connect: Deep Tech Edition, bringing together founders, investors, and industry leaders from across Germany’s deep tech ecosystem.
Represented by Daniel Last, eversyn presented its innovation during the startup pitch session.
The event enabled valuable exchanges, new connections, and engagement with investors and ecosystem partners.

Excited to announce our sponsorship & participation in the "Advances and New Horizons in Glycobiology" conference in London, December 3-5, 2024.

Rachel will present the future of precision biotransformation in a five-minute pitch to potential investors. Together with Sebatian, she will be also available at the eversyn booth to answer all your questions about eversyn’s unique technology for nutrition and biopharma 🚀

The ISC Vietnam Team, together with partners, mentors, experts, and friends, provided 6 German startups with an information package about Vietnam as a target market, as well as crucial business contacts with potential cooperation partners, such as distributors, customers, suppliers, and research partners.

We are thrilled to announce that Eversyn is proud to support the organization of GlycoBioTec2025! As a leading force in advancing glycobiotech innovations, we are excited to contribute to this event that promises to drive the future of glycoscience and its application.

The project aims to delineate the mechanisms and effects of Human Milk Oligosaccharides (HMOs) on the immune system and the intestinal epithelium in relevance to non- communicable diseases, while at the same time, investigate methods for large scale production for more complex, functional HMOs.

After being voted by Plug and Play's Food & Beverage partners, eversyn has been accepted into Plug and Play’s Accelerator - Food & Beverage - Batch 15! Over the next three months, we're set to immerse ourselves in exclusive workshops, personalized 1:1 #mentor sessions, and access to private #dealflows, all thanks to the expansive network provided by Plug and Play.

Global Investor Forum offers up to 30 start-up companies in the field of biotech, medtech and AI & digital health to present themselves to leading investors and other potential partners.

Rachel who manages the business development of eversyn will present the future of cell-free biosynthesis in a three-minute pitch to potential partners and investors.

Alberto who is spearheading the bioprocess development of eversyn will present at the eighteenth annual BIO-Europe Spring®, March 18-20, 2024, in Barcelona, Spain.

We are pleased to join the 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) that will take place on the 28th - 29th February 2024 back at the Hilton Zurich Airport Hotel. The event will be part of the Sachs Spring Life Sciences Week, which will also incorporate the 5th Annual European HealthTech CEO Forum.

We cordially invite you to join us at our exclusive pitching session, where we'll unveil how precision biotransformation can become a game changer in nutrition and biopharma production. Our founder - Dr. Thomas Rexer is eager to share our vision and engage in thought-provoking discussions with you.

The startup week at Martin Luther University Halle-Wittenberg (MLU ) could not have kicked off with more momentum. On the very first day, the university's transfer and start-up service transformed the Volkspark in Halle into a stage for the Startup FOCUS Pitch & Connect event. Support was provided by the International Startup Campus and Univations GmbH.

🚀 Karim is set to unveil our Glycoengineering Toolbox, maximizing control over glycosylation for your biologics.

Rachel who manages the business development of eversyn will present the future of precision biotransformation in a three-minute pitch to potential investors. Rachel & Volker (eversyn's CEO) will be also available at the eversyn booth to answer all your questions about eversyn’s unique technology for nutrition and biopharma 🚀

eversyn today announced the appointment of Dr. Ing. Volker Landschütze as its Chief Executive Officer, following an intensive talent search supported by Max Planck Innovation. For the first time since founded, eversyn has its first CEO.

This FASEB Science Research Conference (SRC) will explore the novel findings on human milk composition and bioactive function. Participants for this meeting will be principal scientists from various sectors who are interested in the breast milk area of research.

For preparing a spin-off, engaging in fundraising, creating a vision and strategy for growing, foundation and product positioning.

Our whole team will be present in person at the GlycoBioTec 2023. We are looking forward to meeting you at our booth in the exhibition hall. Moreover, we will present our technology with a talk at the conference. Stay tuned for more information.

We are delighted to announce that our team is supported by an EXIST research transfer grant over 0.9 Mio € from the Federal Ministry for Economics and Climate Action. eversyn will use the proprietary, cost-efficient and highly scalable technology for the synthesis of nucleotide sugars and valuable oligosaccharides.